Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.
about
AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progressionMolecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targetsProstate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancerThe role of SPINK1 in ETS rearrangement-negative prostate cancersRecurrent rearrangements in prostate cancer: causes and therapeutic potentialDiscovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate TissueEvaluation and prognostic significance of ACAT1 as a marker of prostate cancer progressionPrognostic outlier genes for enhanced prostate cancer treatment.Targeted assembly of short sequence reads.Discovering and understanding oncogenic gene fusions through data intensive computational approachesAssociation of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancerA kernel-based integration of genome-wide data for clinical decision support.Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancerNew strategies in prostate cancer: translating genomics into the clinicThe role of epithelial plasticity in prostate cancer dissemination and treatment resistanceCharacterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y.ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patientsInactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancerOncogenic activation of ERG: A predominant mechanism in prostate cancer.Genetic and epigenetic changes in human prostate cancerTMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.RNA biomarkers to facilitate the identification of aggressive prostate cancerBiomarkers and the genetics of early neoplastic lesions.Regulators of gene expression as biomarkers for prostate cancerERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.Fusion in the ETS gene family and prostate cancer.The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisNovel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment.Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer.Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectivesTMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line.Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer studyGenetic variation in the upstream region of ERG and prostate cancer.Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men.
P2860
Q21203668-C8FD9240-9DF8-4467-B76B-10CCE6B7695EQ24629083-6562F14C-388D-4D38-98B6-1D7CEA18C695Q24645528-ACDDD54B-3D47-479E-822E-F485E6075687Q24647020-BCD9A6C1-0757-4458-9E0A-68CD1CA5CEB5Q26851525-46279395-23D9-4C9E-8BBE-B1F9B6F4D603Q26997884-E6F241C2-4CB8-4CFD-9102-686D45C34BCEQ28303423-A7A0315C-9D62-4ED8-8026-E5167CBF4CA2Q30244674-C082BD9D-E696-4B4F-A4D8-2692CF37A667Q31011171-5174EB7F-85DA-4D7E-9E81-0D105B84283BQ31083417-C173BDE0-E933-4768-92C5-D32ACDDA121DQ33359279-7AC93320-892A-4748-93A3-BE2124A18A01Q33390454-C33F8221-7EBB-4BDE-8C4B-16F6B2F9152EQ33428301-B9EF727F-E1E6-4210-9350-38C1DE856176Q33723651-F1FC5CC5-195E-4667-9633-9DEC972BE202Q33862890-41ADC49F-0B2F-4487-9CBB-D575E10B6524Q34007943-A828FBEB-0467-4B29-804B-6E121EB7F448Q34505037-538412C8-60C4-4828-B5D5-F9DAE016EE48Q34580034-8F544358-50D7-4B36-B0E5-5760D9761F2AQ35091321-ED13A2AB-6F57-42E9-A094-F0710EBDD408Q35199287-937B6D82-B710-44C7-9480-30FB78D32268Q35582540-63A5A556-17AA-453A-8151-0CBAA121463BQ35685920-57EA465A-0482-4105-9594-24346509707FQ36022274-E8A4FBBE-913A-4DA6-86B2-E1C9418FFA68Q36147719-2F6EF43C-5178-4275-80BE-0DA00587A3A1Q36260364-D5F42D85-4E7C-4F8B-9A30-E2AABE9EA6B1Q36340108-CCFAC6CE-EF8A-4E19-B5FC-ABFC0AC6628BQ36439912-B0F49DC8-F3FF-4385-AD71-10B5F235E5F4Q36710981-F1A58BD4-BD77-49D1-B5B0-A90CA363D470Q36860976-FEE45CE7-D096-4F3C-B860-D5EA4A8349BCQ36882701-BE26AD80-6F75-4682-B125-F4DF0B8D1BE9Q36899790-3FC8D9A2-4673-42C8-B9B5-DE17A93399C2Q36901964-AA06D7B4-237A-4A83-BE90-C145E8EE25A6Q36923138-4DC7032A-0ECA-4D32-A835-5FBF722255E0Q36972125-19F6C860-F763-4F8C-AC81-0D6A551F0E81Q37020132-573A68E8-C38D-4217-B254-A63A31222C9DQ37046014-88DF30C5-6565-4CF3-9520-E1523C53D7C8Q37078208-BBEACBD3-AEEB-441C-8927-FA12B579A78FQ37100101-C3566D91-4ED3-4099-AC81-B29812486FCBQ37127440-4CB4F09C-E1A2-425C-9E27-99C295062969Q37139054-6C484CD9-B662-4CB7-A27C-F5FB878841A6
P2860
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Expression of the TMPRSS2:ERG ...... for localised prostate cancer.
@ast
Expression of the TMPRSS2:ERG ...... for localised prostate cancer.
@en
type
label
Expression of the TMPRSS2:ERG ...... for localised prostate cancer.
@ast
Expression of the TMPRSS2:ERG ...... for localised prostate cancer.
@en
prefLabel
Expression of the TMPRSS2:ERG ...... for localised prostate cancer.
@ast
Expression of the TMPRSS2:ERG ...... for localised prostate cancer.
@en
P2093
P2860
P356
P1476
Expression of the TMPRSS2:ERG ...... for localised prostate cancer.
@en
P2093
A Stanimirovic
D A Loblaw
J Trachtenberg
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604054
P407
P577
2007-10-30T00:00:00Z